Checks whether a heart failure medicine taken before hospital affects short-term outcomes
Compares short-term outcomes in hospitalized adults with heart failure who took ARNI before admission.
Plain-language title generated from the registry record
Registry title: Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
Key facts
- Where
- Al Mansurah, EgyptSee the site
Where in Egypt
- Mansoura university HospitalAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Future University in Egypt
- Trial code
- NCT07347925
- Record updated
- 16 January 2026
- Original description
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes.Read full original descriptionShow less
Evaluating the Impact of Pre-Hospital Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy on Short-Term Clinical Outcomes in Heart Failure Patients With Reduced Ejection Fraction: A Comparative Study
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes.
The study will compare two groups of participants: those who were already taking ARNI before coming to the hospital and those who were not. Information will be collected from medical records during the hospital stay, including heart-related events, kidney-related events, and how long participants stay in the hospital.
Some participants will also be followed for a short period after discharge. This study may help improve understanding of outcomes associated with ARNI use in people with heart failure in routine clinical care.
Inclusion: >= 18 years, male or female EF <40%.
Exclusion: EF>40% Pregnancy or breastfeeding.